World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
82
Citations
22937
World Ranking
1512
National Ranking
761

Martin A. Cheever publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Martin A. Cheever sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 202 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Martin A. Cheever D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Martin A. Cheever sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 82 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Martin A. Cheever is affiliated with the University of Washington in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a focused emphasis on Oncology, Immunology, Dermatology, Pathology and Forensic Medicine, and Molecular Biology.

The scientist's work concentrates on several main topics, including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cutaneous lymphoproliferative disorders research
  • Lymphoma Diagnosis and Treatment
  • T-cell and B-cell Immunology
  • Viral-associated cancers and disorders

Martin A. Cheever has frequently published in a range of journals, with the most common venues being:

  • Journal for ImmunoTherapy of Cancer
  • Clinical Cancer Research
  • Science Translational Medicine
  • Cancer Research
  • Nature Communications

Notable recent papers authored or co-authored by Martin A. Cheever include:

  • "Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma," 2021, Nature Communications
  • "Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer," 2021, Clinical Cancer Research
  • "Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma," 2021, Journal for ImmunoTherapy of Cancer
  • "Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets," 2020, Nature Cancer
  • "Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy," 2022, Science Translational Medicine

The scientist collaborates regularly with several co-authors, including:

  • Steven P. Fling
  • Nirasha Ramchurren
  • Leonard D'Amico
  • Judith C. Kaiser
  • Chihiro Morishima

Best Publications

  • The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

    Martin A. Cheever;Martin A. Cheever;James P. Allison;Andrea S. Ferris;Olivera J. Finn

  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar

  • PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

    Martin A. Cheever;Celestia S. Higano

  • Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

    Mary L. Disis;Emanuel Calenoff;Graham McLaughlin;Ann E. Murphy

  • Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia

    E D Thomas;R A Clift;A Fefer;F R Appelbaum

  • Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

    Mary L. Disis;Theodore A. Gooley;Kristine Rinn;Donna Davis

  • Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

    Mary L. Disis;Kenneth H. Grabstein;Paul R. Sleath;Martin A. Cheever

  • Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

    Mary L. Disis;Helga Bernhard;Faith M. Shiota;Susan L. Hand

  • High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

    Mary L. Disis;Serenella M. Pupa;Julie R. Gralow;Ruggero Dittadi

  • Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

    P D Greenberg;M A Cheever;A Fefer

  • Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.

    Philip D. Greenberg;Donald E. Kern;Martin A. Cheever

  • Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

    M A Cheever;P D Greenberg;A Fefer;S Gillis

  • Generation of Immunostimulatory Dendritic Cells from Human CD34+ Hematopoietic Progenitor Cells of the Bone Marrow and Peripheral Blood

    Helga Bernhard;Mary L. Disis;Shelly Heimfeld;Susan Hand

  • Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369–377, Results in Short-lived Peptide-specific Immunity

    Keith L. Knutson;Kathy Schiffman;Martin A. Cheever;Mary L. Disis

  • Twelve immunotherapy drugs that could cure cancers

    Unknown

  • Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

    Mary L. Disis;Julie R. Gralow;Helga Bernhard;Susan L. Hand

  • Identification of Genes Overexpressed in Head and Neck Squamous Cell Carcinoma Using a Combination of Complementary DNA Subtraction and Microarray Analysis

    Douglas B. Villaret;Tongtong Wang;Davin Dillon;Jiangchun Xu

  • HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

    Mary L. Disis;Martin A. Cheever

  • T-cell immunity to the joining region of p210BCR-ABL protein

    Wei Chen;David J. Peace;Douglas K. Rovira;Sheng Guo You

  • Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic Leukemia: A Prospective Comparison

    Appelbaum Fr;Dahlberg S;Thomas Ed;Buckner Cd

  • Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.

    Alexander Gaiger;Valerie Reese;Valerie Reese;Mary L. Disis;Mary L. Disis;Martin A. Cheever;Martin A. Cheever

  • In Vitro Generation of Human Cytolytic T-Cells Specific for Peptides Derived from the HER-2/neu Protooncogene Protein

    Mary L. Disis;Joseph W. Smith;Ann E. Murphy;Wei Chen

  • Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.

    Unknown

Frequent Co-Authors

Alexander Fefer
Alexander Fefer University of Washington
Philip D. Greenberg
Philip D. Greenberg Fred Hutchinson Cancer Research Center
Mary L. Disis
Mary L. Disis University of Washington
E. Donnall Thomas
E. Donnall Thomas University of Washington
Rainer Storb
Rainer Storb Fred Hutchinson Cancer Research Center
Julie R. Gralow
Julie R. Gralow American Society of Clinical Oncology
Wei Chen
Wei Chen University of Minnesota
Keith M. Sullivan
Keith M. Sullivan Duke University
Jean E. Sanders
Jean E. Sanders Fred Hutchinson Cancer Research Center
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens diverse career opportunities in healthcare and research. Many students pivot into nursing roles to gain clinical experience, making programs like the best online RN programs for non nurses a popular choice. These programs cater to individuals transitioning into nursing without prior experience, bridging gaps efficiently.

For those seeking quicker entry into nursing, accelerated options like absn programs with high acceptance rates provide accessible pathways. These programs are designed to fast-track learning while maintaining quality education standards.

Additionally, practical nursing is a viable pathway through accredited LPN programs easy to get into. These prepare students for essential caregiving roles, often requiring shorter study durations and offering flexible scheduling.

For advanced practice, exploring easy nurse practitioner programs to get into can help immunology graduates enhance their scope of practice. These programs balance accessibility with the depth of training needed for autonomous patient care.

Best Scientists Citing Martin A. Cheever

Trending Scientists